Sionna Therapeutics financials
$5.15+0.59%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$32.5M | -$29.6M | -$23.6M | -$23.8M | -$21.7M | -$19.7M |
| Net income | -$29.9M | -$26.8M | -$20.4M | -$20.3M | -$18.1M | -$16.5M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-0.66 | $-0.60 | $-0.46 | $-0.46 | $-0.41 | $-0.62 |
| EBITDA | -$32.3M | -$29.4M | -$23.5M | -$23.6M | -$21.6M | -$19.5M |
| Operating cash flow | -$22.2M | -$21.8M | -$16.6M | -$15.2M | -$18.2M | -$16.3M |
| Free cash flow | -$22.2M | -$21.8M | -$16.8M | -$15.3M | -$18.2M | -$16.4M |
| Diluted shares | 45.1M | 44.9M | 44.9M | 44.3M | 44.1M | 26.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $63.3M | $63.3M | $58.5M | $50.8M | $41.0M | $82.7M |
| Short-term investments | $147.7M | $152.8M | $177.4M | $197.5M | $221.6M | $187.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $283.2M | $305.0M | $326.0M | $339.3M | $352.0M | $369.7M |
| Total liabilities | $17.5M | $16.8M | $19.1M | $17.6M | $15.6M | $17.9M |
| Shareholders' equity | $265.8M | $288.2M | $306.8M | $321.7M | $336.4M | $351.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology